Retatrutide
Triple Agonist — Maximum Fat Loss
The most advanced weight loss peptide — triple GLP-1/GIP/Glucagon receptor agonist. Phase 2 trials show up to 24% body weight reduction. The strongest fat loss compound available.
Starting From
$189.99
Sold By
Apollo Peptide Sciences
Suggested Protocol
Dose escalation: 1mg weekly for 4 weeks, increasing gradually to target doses of 4–12mg weekly over 12–24 weeks. The extended escalation is essential with retatrutide due to its potency. Maintenance at 8–12mg weekly. SubQ injection once weekly.
24.2%
Body Wt. Loss
3 (Triple)
Receptors
NEJM 2023
Trial Source
The Third Receptor: How Adding Glucagon Broke the Fat Loss Ceiling
Retatrutide represents the frontier of metabolic peptide research — a triple GIP/GLP-1/Glucagon receptor agonist that surpasses both semaglutide and tirzepatide in documented fat loss efficacy. Where tirzepatide added GIP activation to GLP-1, retatrutide adds glucagon receptor agonism as a third mechanism, producing fat oxidation effects through three independent pathways simultaneously.
The glucagon receptor component is the key differentiator. Glucagon classically drives glycogenolysis and fat mobilization from the liver — the "fasting signal." By combining glucagon receptor activation with GLP-1's appetite suppression and GIP's insulin sensitization, retatrutide creates a metabolic state that simultaneously reduces caloric intake (GLP-1) and dramatically increases fat oxidation (glucagon) while maintaining metabolic homeostasis (GIP). The theoretical elegance is matched by the clinical results.
Phase 2 trial data published in the New England Journal of Medicine demonstrated a mean body weight reduction of 24.2% at 48 weeks with the 12mg dose — the highest fat loss efficacy ever documented for any compound in peer-reviewed clinical research. At the 8mg dose, average reduction was 22.8%. These outcomes represent approximately 2–5% greater absolute weight loss than tirzepatide at equivalent timeframes.
The compound also demonstrated significant reductions in liver fat (critical for metabolic health), improvements in cardiovascular risk markers, and reductions in waist circumference that exceed the scale weight reductions alone.
What Glucagon Does
The Missing Mechanism: How Glucagon Receptor Agonism Creates Active Fat Oxidation Between Doses
GLP-1 suppresses appetite and slows gastric emptying. GIP improves insulin sensitivity and enhances fat storage inhibition. Glucagon does something categorically different: it signals the liver to mobilize stored fat and directly increases fat oxidation — the "fasting signal" that drives the body to burn rather than store. By combining all three, retatrutide creates a metabolic environment that simultaneously reduces caloric intake (GLP-1), improves how those calories are processed (GIP), and actively drives fat burning between meals (glucagon). No other compound in research achieves all three simultaneously, and this is why the Phase 2 outcomes exceeded everything before it.
The Phase 2 Data
24.2% in 48 Weeks: What the NEJM Study Actually Showed — and What It Didn't
The Phase 2 retatrutide data published in the New England Journal of Medicine (2023) showed 24.2% average body weight reduction at the 12mg dose over 48 weeks — the highest fat loss efficacy ever documented in peer-reviewed clinical research at that time. At 8mg, the average was 22.8%. These figures also came with significant reductions in liver fat, waist circumference reductions that exceeded the weight loss percentage (indicating disproportionate visceral fat loss), and cardiovascular marker improvements. What the Phase 2 didn't show: long-term safety beyond 48 weeks, since Phase 3 data is still emerging. Retatrutide is the most potent compound available — and demands the same serious approach any frontier compound does.
Beyond Weight Loss
Hepatic Fat, Visceral Adiposity, and Cardiovascular Risk: The Full Metabolic Profile
Retatrutide's glucagon component drives liver-specific fat mobilization that semaglutide and tirzepatide cannot replicate at the same magnitude. Hepatic fat reduction is critical for metabolic health: liver fat accumulation is strongly associated with insulin resistance, cardiovascular risk, and progression to non-alcoholic fatty liver disease (NAFLD). Retatrutide's Phase 2 data showed hepatic fat reductions that exceeded body weight loss percentages — meaning the liver was being cleared of fat faster than overall body fat loss would predict. For researchers interested in metabolic health outcomes beyond aesthetics, this is retatrutide's most clinically significant differentiator.
Key Benefits
Up to 24.2% body weight reduction in Phase 2 clinical trials — highest ever documented
Triple receptor activation: GLP-1 (appetite) + GIP (insulin) + Glucagon (fat oxidation)
Significantly reduces hepatic fat — addressing metabolic liver disease
Superior visceral fat reduction vs. dual GLP-1/GIP compounds
Improves cardiovascular risk markers across all measured parameters
Maintains lean muscle mass during fat loss phase better than diet alone
Weekly injection protocol — same convenience as semaglutide/tirzepatide
Available in 10mg, 15mg, 30mg, and 60mg vials from Apollo
Full Protocol
Dose escalation: 1mg weekly for 4 weeks, increasing gradually to target doses of 4–12mg weekly over 12–24 weeks. The extended escalation is essential with retatrutide due to its potency. Maintenance at 8–12mg weekly. SubQ injection once weekly.
More in Weight Management
View All
Semaglutide
The compound behind Ozempic/Wegovy. GLP-1 receptor agonist producing significant appetite suppression, fat loss, and metabolic improvement with once-weekly dosing.
